Santhera Obtains US Patent for the Use of Catena® in the Treatment of Muscular Dystrophies
September 13, 2011 leilanifera

The vision of the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) is to extend and improve the function, quality of life and life span for all individuals diagnosed with DMD. This program is administered by the US Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

READ MORE
http://www.santhera.com/index.php?docid=212&vid&lang=en&newsdate=201108&newsid=1540047&newslang=en
Department of Defense Duchenne Muscular Dystrophy Research Program
July 13, 2011 leilanifera

Liestal, Switzerland, August 24, 2011 – Santhera Pharmaceuticals (SIX: SANN) announced today that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name Catena®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.

READ MORE